Evidence map›Paper›PMID 30350003›Full record

ArticleNanoscale research letters2018

Curcumin-loaded chitosan-bovine serum albumin nanoparticles potentially enhanced Aβ 42 phagocytosis and modulated macrophage polarization in Alzheimer's disease.

Rui Yang, Yan Zheng, Qingjun Wang, Liang Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rui YangThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Yan ZhengSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Qingjun WangThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121000, People's Republic of China. qingjunwang999@163.com.
Liang ZhaoSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China. liangzhao79@163.com.
Jinzhou Medical University · CN

Funding

the Natural Science Foundation of Liaoning Province 2015020348
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder in the elderly population. In the treatment of AD, some obstacles, including drug penetration difficulty through the blood-brain barrier (BBB), inadequate clearance of the Aβ peptide, and the massive release of inflammatory factors, must be urgently overcome. To solve these problems, we developed special and novel nanoparticles (NPs) made of chitosan (CS) and bovine serum albumin (BSA) to enhance the penetration of drugs through the BBB. Curcumin as a potent anti-inflammatory agent was used to increase the phagocytosis of the Aβ peptide. The results demonstrated that curcumin-loaded CS-BSA NPs effectively increased drug penetration through the BBB, promoted the activation of microglia, and further accelerated the phagocytosis of the Aβ peptide. Furthermore, curcumin-loaded CS-BSA NPs inhibited the TLR4-MAPK/NF-κB signaling pathway and further downregulated M1 macrophage polarization. This study suggested that curcumin-loaded CS-BSA NPs hold the potential to enhance Aβ 42 phagocytosis through modulating macrophage polarization in AD.

Indexed as

Alzheimer’s diseaseAβ peptideBlood–brain barrierCurcuminNanoparticles

Identifiers

PMID30350003
PMCPMC6197340
OpenAlexW2897352256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.